Stocks Health care ROIV
NASDAQ · Health careRoivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. brought in $41.1M of revenue over the twelve months to September 30, 2026, up 102.1% from a year earlier. It posted a net loss of $344.4M. In fiscal 2025 capital spending exceeded operating cash flow by $758.6M. At September 30, 2026 it held $1.6B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Roivant Sciences Ltd.
- Net worth
- Roivant Sciences Ltd. has a market value (market cap) of $29.4B at the latest share price, and shareholders' equity of $4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $8.3M (-71.6% year on year), with a net loss of $299.8M. Over the 12 months to September 30, 2026: revenue $41.1M, net loss $344.4M.
- Cash flow
- In fiscal 2025 operations used $750.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Roivant Sciences Ltd.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Roivant Sciences Ltd. does
Roivant Sciences Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ROIV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $8.3M | -$299.8M | -$0.54 | -$758.6M |
| 2024 | $29.1M | -$172M | -$0.24 | -$844.1M |
| 2023 | $32.7M | $4.3B | $5.23 | -$766.7M |
| 2023 | $31.5M | -$1B | -$1.42 | -$856.1M |
| 2022 | $55.3M | -$845.3M | -$1.26 | -$695.2M |
| 2022 | $23.8M | -$809.2M | -$1.28 | -$557.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ROIV ranks in Health care
Latest SEC filings
What Roivant Sciences Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 2,136% to $35.1M versus the same quarter last year; diluted EPS -$0.27 versus -$0.17.
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 21, 2026
- October 5, 2026Activist stake changed SCHEDULE 13D/A
- September 18, 2026
- September 8, 2026
- August 28, 2026Other event 8-K
- August 27, 2026
Insider trades
What the people running Roivant Sciences Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $74.4M worth of shares in the last 90 days and bought none on the open market. Most of the selling (51%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Venker EricPresident & Immunovant CEO | Soldpre-planned (10b5-1) | 200,000 | $7.3M |
| October 28, 2026 | Venker EricPresident & Immunovant CEO | Soldpre-planned (10b5-1) | 200,000 | $7.3M |
| October 23, 2026 | Momtazee James CDirector | Received as pay | 383 | - |
| October 23, 2026 | Momtazee James CDirector | Shares withheld for tax | 77 | $2.8K |
| October 23, 2026 | Oren IlanDirector | Received as pay | 810 | - |
| October 23, 2026 | Epperly Melissa B,Director | Received as pay | 513 | - |
| October 23, 2026 | Epperly Melissa B,Director | Shares withheld for tax | 116 | $4.2K |
| October 20, 2026 | Venker EricPresident & Immunovant CEO | Soldpre-planned (10b5-1) | 185,856 | $6.5M |
Who owns ROIV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Roivant Sciences Ltd.13D, may seek influence | 55.9% | December 12, 2025 |
| Fmr LLC13G, passive with 1 related filers | 10.3% | March 6, 2026 |
| BlackRock, Inc.13G, passive | 8.2% | October 27, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 135,717,960 shares in total, about $5.53B at the last price.
| Holder | Shares |
|---|---|
| Ramaswamy Vivek10% owner | 33,653,755 |
| Gold Daniel AllenDirector | 22,654,98113,689,166 held indirectly |
| Sukhatme MayukhPresident & CIO, Director | 18,563,884 |
| Gline MatthewCEO, Director | 16,549,136 |
| Manchester Keith SDirector | 15,442,62313,689,166 held indirectly |
| QVT Financial LPDirector by Deputization | 13,689,16613,689,166 held indirectly |
| Torti FrankPresident and Vant Chair | 13,495,893 |
| Venker EricPresident & Immunovant CEO | 999,154 |
| Pulik RichardCFO | 269,681 |
| Oren IlanDirector | 124,490 |
Questions about ROIV
What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a company in the Health care sector, listed on NASDAQ as ROIV. Its shares trade on NASDAQ under the ticker ROIV.
What is Roivant Sciences Ltd.'s net worth?
Roivant Sciences Ltd. has a market value (market cap) of $29.4B at the latest share price, and shareholders' equity of $4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Roivant Sciences Ltd. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $344.4M on revenue of $41.1M.
How much revenue does Roivant Sciences Ltd. make?
Over the twelve months to September 30, 2026 Roivant Sciences Ltd. reported revenue of $41.1M. That is 102.1% more than a year earlier.
When did Roivant Sciences Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Roivant Sciences Ltd.'s next earnings report?
Roivant Sciences Ltd.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ROIV with
Follow ROIV
Get an email when Roivant Sciences Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Roivant Sciences Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.